Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.
Canestri
Ana
A
Cisse
Mamadou
M
Marcelin
Anne-Geneviève
AG
Peytavin
Gilles
G
Traore
Emmanuel
E
Assoumou
Lambert
L
Traore
Ousmane
O
Koita
Victoria
V
Diallo
Fodie
F
Sangare
Awa Thiero
AT
Sidibé
Mayrama Koita
MK
Calvez
Vincent
V
Sylla
Aliou
A
Katlama
Christine
C
Tubiana
Roland
R
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008302:Mali; D008875:Middle Aged; D010865:Pilot Projects; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D017320:HIV Protease Inhibitors; D019469:Indinavir; D019438:Ritonavir